HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
BACKGROUND:Cardiovascular disease (CVD) is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), for whom the absolute risk of cardiovascular events is similar to people who have existing coronary artery disease. This is an update of a review published in 2009...
Main Authors: | Suetonia C. Palmer, Sankar D. Navaneethan, Jonathan C. Craig, David D. Johnson, Vlado Perkovic, Jorgen Hegbrant, Giovanni F. M. Strippoli |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Paulista de Medicina
|
Series: | São Paulo Medical Journal |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802014000500314&lng=en&tlng=en |
Similar Items
-
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
by: Suetonia C. Palmer, et al. -
Effects of HMG-CoA Reductase Inhibitors (Statins) On Bone Mineral Density and Metabolism
by: Nehir Samancı, et al.
Published: (2004-06-01) -
Pharmacogenetics of HMG-CoA reductase inhibitors (statins): perspectives of individualized, genotype-based therapy
by: D. A. Sychev, et al.
Published: (2006-02-01) -
An Assessment of Oral Health in Hypertensive Patients Treated with HMG-CoA Reductase Inhibitors (Statins)
by: Amir AM Al-Joboury, et al.
Published: (2015-12-01) -
Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol
by: Shi-You Jiang, et al.
Published: (2018-12-01)